PMID 32966863
User experimentation suggests that longer initial treatment periods (6+ months continuous) support better benefit retention during subsequent breaks, complete discontinuation breaks of 1-2 months show acceptable benefit maintenance for most users, and very extended breaks (3-6+ months) increase risk of regression toward pre-treatment baseline particularly for short initial treatment courses
Issues like tendonitis, rotator cuff pain, tennis elbow, or chronic sprains often heal slowly
Though extremely rare, theres a small risk that vascular occlusion caused by dermal fillers could lead to blood clot formation
Ask for the independent labs Certificate of Analysis for that production run so you can match the peak and mass yourself, and for any live-animal or cell work add endotoxin and sterility testing on top
Some drug, but probably not enough, got through For AOD9604, large molecule size wouldnt have reduced bioavailability to zero, and the use of polyethylene glycol as an excipient may have increased bioavailability slightly13, however there is the distinct possibility that not enough of the drug got through the gastrointestinal tract to make a therapeutic difference. In summation: Given the stark contrast between the biohackers and the institutional scientists, we have the selective release of fats from the fat cells in obese or lean individuals (depending on who you ask) to justify using AOD-9604 for biohacking weight loss
